OKYO
NASDAQOKYO Pharma Limited
Price$1.54+0.04 (+3.00%)
01:45 PM07:45 PM
News · 26 weeks79+189%
2026-01-252026-07-19
Mix4290d
- Insider17(40%)
- SEC Filings12(29%)
- Other11(26%)
- Leadership1(2%)
- Offering1(2%)
Latest news
25 items- INSIDERCHIEF EXECUTIVE OFFICER Dempsey Robert John was granted 15,000 shares (SEC Form 4)4 - OKYO Pharma Ltd (0001849296) (Issuer)
- INSIDERDirector Brancaccio John P was granted 5,000 shares, increasing direct ownership by 17% to 35,201 units (SEC Form 4)4 - OKYO Pharma Ltd (0001849296) (Issuer)
- INSIDERDirector Cerrone Gabriele M was granted 22,500 shares (SEC Form 4)4 - OKYO Pharma Ltd (0001849296) (Issuer)
- INSIDERCHIEF DEVELOPMENT OFFICER Jacob Gary S was granted 3,500 shares, increasing direct ownership by 3% to 112,420 units (SEC Form 4)4 - OKYO Pharma Ltd (0001849296) (Issuer)
- SECSEC Form 6-K filed by OKYO Pharma Limited6-K - OKYO Pharma Ltd (0001849296) (Filer)
- PROKYO Pharma Announces Purchase of Shares by DirectorLONDON and NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that OKYO Pharma’s Non-Executive Director, John Brancaccio has purchased 5,000 of the Company’s ordinary shares on NASDAQ at $1.48 per share, bringing his total holding to 35,201 shares. About OKYO Pharma OKYO Pharma Limited (NASDAQ:OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, with ordinary sha
- SECSEC Form 6-K filed by OKYO Pharma Limited6-K - OKYO Pharma Ltd (0001849296) (Filer)
- PROKYO Pharma Announces Purchase of Shares by Chief Executive OfficerLONDON and NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that OKYO Pharma’s Chief Executive Officer, Robert J. Dempsey, has purchased 15,000 of the Company’s ordinary shares on NASDAQ at $1.54 per share. About OKYO Pharma OKYO Pharma Limited (NASDAQ:OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, with ordinary shares listed for trading on the Nasdaq Cap
- INSIDERCHIEF MEDICAL OFFICER Mantelli Flavio was granted 20,000 shares (SEC Form 4)4 - OKYO Pharma Ltd (0001849296) (Issuer)
- SECSEC Form 6-K filed by OKYO Pharma Limited6-K - OKYO Pharma Ltd (0001849296) (Filer)
- SECSEC Form 6-K filed by OKYO Pharma Limited6-K - OKYO Pharma Ltd (0001849296) (Filer)
- PROKYO Pharma Announces Purchase of Shares by Chief Development Officer and DirectorLONDON and NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that Gary S. Jacob, PhD, Chief Development Officer and Director of OKYO Pharma has increased his holdings with the purchase of 3,500 of the Company’s ordinary shares on NASDAQ at $1.40 per share, bringing his total holding to 112,420 ordinary shares. About OKYO Pharma OKYO Pharma Limited (NASDAQ:OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal
- SECSEC Form 6-K filed by OKYO Pharma Limited6-K - OKYO Pharma Ltd (0001849296) (Filer)
- PROKYO Pharma Announces Purchase of Shares by Chief Medical OfficerLONDON and NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that OKYO Pharma’s Chief Medical Officer, Flavio Mantelli, MD, PhD, has purchased 20,000 of the Company’s ordinary shares on NASDAQ at $1.40 per share. About OKYO Pharma OKYO Pharma Limited (NASDAQ:OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, with ordinary shares listed for trading on the Nasda
- INSIDERDirector Cerrone Gabriele M was granted 25,000 shares (SEC Form 4)4 - OKYO Pharma Ltd (0001849296) (Issuer)
- SECSEC Form 6-K filed by OKYO Pharma Limited6-K - OKYO Pharma Ltd (0001849296) (Filer)
- PROKYO Pharma to Present at the H.C. Wainwright 6th Annual Ophthalmology Virtual ConferenceLONDON and NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced a presentation at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference being held on Wednesday, July 22, 2026. Details of the event are as follows: Presenter: Robert J. Dempsey, Chief Executive Officer, Flavio Mantelli MD, PhD, Chief Medical OfficerDate/Time: Wednesday, July 22, 12:30 PM ETLocation: VirtualRegister to Attend: H.C. Wainwright Registration About OKYO PharmaOKYO Pharma Limited (NASDAQ:OKYO) i
- SECSEC Form 6-K filed by OKYO Pharma Limited6-K - OKYO Pharma Ltd (0001849296) (Filer)
- PROKYO Pharma Announces Purchase of Shares by ChairmanLONDON and NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that its Chairman, Mr. Gabriele Cerrone, through Panetta Partners Ltd, an entity in which he has a beneficial interest, has increased his holdings with the purchase of 25,000 ordinary shares at $1.40 per share, bringing his total holding to 10,851,416 ordinary shares, which is 20.51% of issued share capital. About OKYO Pharma OKYO Pharma Limited (NASDAQ:OKYO) is a clinical-stage biopharmaceutical company developing in
- SECSEC Form 6-K filed by OKYO Pharma Limited6-K - OKYO Pharma Ltd (0001849296) (Filer)
- SECSEC Form 20-F filed by OKYO Pharma Limited20-F - OKYO Pharma Ltd (0001849296) (Filer)
- PROKYO Pharma Announces Filing of Annual Report with Strengthened Cash Position and Accelerated Phase 3 PlansLONDON and NEW YORK, July 20, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced the filing of its Annual Report on Form 20-F for the fiscal year ended March 31, 2026, with the U.S. Securities and Exchange Commission (SEC). The report is available on the SEC’s website and the Company’s investor relations page. In conjunction with the filing, the Company provided a positive corporate update on its financial strength and clinical momentum. "We are pleased to announce the filing of our annual report, w
- SECSEC Form 6-K filed by OKYO Pharma Limited6-K - OKYO Pharma Ltd (0001849296) (Filer)
- PROKYO Pharma Reports Positive Feedback from FDA Type D Meeting and Accelerates Urcosimod into Global Phase 3 Pivotal Trial for Neuropathic Corneal PainFDA alignment on a single-dose Phase 3 study design and potential single-trial registration pathway further strengthens the Company's clinical development program for urcosimodCompany unveils NEPTUNE (Neuropathic Eye Pain Treatment with Urcosimod & Nerve Evaluation), a global trial in the United States and EuropeStudy design finalized to enroll approximately 111 subjects in a 2:1 randomization of 0.05% urcosimod versus placeboTo address the significant unmet medical need, the company plans to seek FDA Breakthrough Therapy Designation (BTD), which may further accelerate the development and review pathway LONDON and NEW YORK, July 08, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OK
- SECSEC Form 6-K filed by OKYO Pharma Limited6-K - OKYO Pharma Ltd (0001849296) (Filer)
OKYO FAQ
7 questionsWhat does OKYO Pharma Limited do?
OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. It is developing OK-101 for the treatment of dry eye disease; and OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. The company is also developing chemerin and chemerin analogues to treat the cytokine release syndrome associated with COVID-19 infections and other conditions, such as acute respiratory distress syndrome. OKYO...Where does OKYO stock trade?
OKYO Pharma Limited (OKYO) is listed on NASDAQ.What sector and industry is OKYO in?
OKYO Pharma Limited operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did OKYO Pharma Limited go public?
OKYO Pharma Limited (OKYO) completed its IPO in 2022.What are analysts saying about OKYO?
OKYO Pharma Limited has had 2 recent analyst actions on file. The most recent action was from Piper Sandler: Overweight with a $700.00 price target on 2026-02-20. Recent price targets range from $500.00 to $700.00.What companies are similar to OKYO?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare OKYO side-by-side with any of them on Quantisnow.How can I track OKYO on Quantisnow?
Quantisnow aggregates OKYO Pharma Limited's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow OKYO to receive live email and push alerts on every new disclosure.